argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
argenx reported Q3 2026 VYVGART global product net sales of $1.7 billion, up 54% year-over-year and 13% sequentially, with basic EPS of $8.07 versus $5.61 a year earlier. The pipeline advanced on multiple fronts: positive Phase 3 ALKIVIA results in IMNM and dermatomyositis with an IMNM sBLA on track by year-end, an ocular myasthenia gravis sBLA submitted, a February 2027 PDUFA date for pediatric gMG, and FB102 advancing to Phase 3 in celiac disease. A Phase 3 topline readout for empasiprubart in MMN is expected in December 2026 — the nearest binary catalyst.
Key figures
- Eps
- 8.07
- Revenue
- 1721000000
- Guidance
- Combined R&D and SG&A expenses now expected to be approximately $4 billion for 2026, including Forte transaction-related costs
- Revenue Yoy
- 54%
- Profit q3
- 506000000
- Revenue qoq
- 13%
- Diluted eps q3
- 7.8
- Basic eps q3 2025
- 5.61
- Profit nine months
- 1344000000
- Operating profit q3
- 486000000
- Product net sales q3 2025
- 1127000000
- Product net sales q3 2026
- 1721000000
- Total operating income q3
- 1751000000
- Forte acquisition cost net
- approximately $2.1 billion
- Cash and current financial assets
- 3.7 billion
- Forte acquisition related expenses in q3
- approximately $150 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.